PMID: 7542020Mar 1, 1995Paper

Granulocyte growth factors: achieving a consensus

Annals of Oncology : Official Journal of the European Society for Medical Oncology
M BoogaertsH Link

Abstract

A consensus meeting held under the auspices of the European School of Oncology concluded that the use of granulocyte growth factors is definitely indicated, or acceptable given existing evidence, in the following circumstances: to alleviate congenital neutropenia; in the mobilisation of peripheral blood progenitor cells for autotransfusion; to encourage engraftment following bone marrow transplantation and in cases of failed engraftment; to support continuation of ganciclovir anti-CMV therapy in certain patients with AIDS, where the switch to foscarnet is contraindicated or where toxicity to foscarnet develops. It was also agreed that there is an overwhelming need for carefully controlled clinical trials in a wide range of indications in which growth factor use may improve outcome. In the majority of tumours, the possible benefit of dose optimisation and intensification, and therefore the role of growth factors in support of such measures has still to be defined. Extramedullary toxicities may in these instances become dose limiting.

Citations

Nov 1, 2003·Intensive Care Medicine·Elie Azoulay, Christophe Delclaux
Aug 12, 2008·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Eric J IpJames Chan
Jul 24, 2008·Bone Marrow Transplantation·I Badell, UNKNOWN EBMT Paediatric Working Party
Feb 14, 2002·British Journal of Haematology·Thomas Lehrnbecher, Karl Welte
Apr 20, 2001·Paediatric Drugs·L M Wagner, W L Furman
Mar 1, 2003·British Journal of Cancer·I Ray-CoquardUNKNOWN ELYPSE study group
Mar 3, 1998·Journal of Pediatric Hematology/oncology·W L FurmanW H Meyer
Sep 6, 2000·British Journal of Haematology·H G PrenticeA G Prentice
Jul 5, 2005·Expert Opinion on Investigational Drugs·F J Lofts, R Pettengell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Expert Opinion on Investigational Drugs
F J Lofts, R Pettengell
Annals of Oncology : Official Journal of the European Society for Medical Oncology
P L R MitchellM Green
British Journal of Nursing : BJN
E JohnsonM Stephens
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
I M GouldJ M van der Meer
© 2021 Meta ULC. All rights reserved